First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study.
about
Treatment of colorectal cancer in the elderlyThe place of targeted agents in the treatment of elderly patients with metastatic colorectal cancerCan we predict toxicity and efficacy in older patients with cancer? Older patients with colorectal cancer as an exampleDecision-making in geriatric oncology: systemic treatment considerations for older adults with colon cancer.First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study.Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies in older adults with metastatic colorectal cancer.Fool's gold, lost treasures, and the randomized clinical trial.Chemotherapy for colorectal cancer in the elderly.Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope.The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers.Treatment of older patients with colorectal cancer: a perspective review.Treatment of colorectal cancer in older patients.Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013.First-line chemotherapy for mCRC—a review and evidence-based algorithm.Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence.Retrospective study as first-line chemotherapy combined anti-VEGF antibody with fluoropyrimidine for frail patients with unresectable or metastatic colorectal cancer.Durable complete remission following anti-EGFR antibodies in recurrent metastatic colorectal cancer.Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial.
P2860
Q26781457-F545138F-F4BD-4F4D-9BBE-E1725C45E7D8Q27011366-463814FE-F552-4573-91F1-85876EEA6A3EQ28069620-9F2A896B-645F-402B-A99F-4BCA5748AE3AQ30244769-4DEE779F-7FB8-4C88-A65C-A43BF108D83AQ33918152-831F00A0-01B3-460B-81B2-DF71D25B0AFEQ34173277-58D75408-8CAC-4D23-A2D0-EFF587CEAA9AQ34669260-B56D76FF-DE8E-40E7-B564-6B75FA9F6159Q35567604-A3EC2D07-A6C7-4D33-B365-E0EDAD031AC0Q36478721-50C2ABE5-A85B-4AD2-B904-CD052F06F786Q37015715-911976B7-F356-489B-A553-3028F4F393B3Q37704350-3F7EA0B9-822E-43B5-8904-1B7F4DE03253Q38050375-1B52ECE5-BC20-4F57-B679-5AF1369CE016Q38216008-FBA8D29A-7517-41C1-BC29-DC47DAD66903Q38228522-61D25262-C9E2-4FAA-83FF-186C5C74562CQ38555200-EDE76C5F-F18E-496D-905F-FBD15258D378Q38961110-C81A9FAD-F9DD-428A-819C-2827E356FC8EQ44102658-47D58D75-5957-44A9-A209-D6FF92B2A546Q48285173-0CC1B178-0991-4E86-B7BE-9C88B3FB0271Q55385744-752E7094-879B-4B60-AB08-0FA7984F3AD9
P2860
First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
First-line cetuximab plus cape ...... rom a Spanish TTD Group Study.
@ast
First-line cetuximab plus cape ...... rom a Spanish TTD Group Study.
@en
type
label
First-line cetuximab plus cape ...... rom a Spanish TTD Group Study.
@ast
First-line cetuximab plus cape ...... rom a Spanish TTD Group Study.
@en
prefLabel
First-line cetuximab plus cape ...... rom a Spanish TTD Group Study.
@ast
First-line cetuximab plus cape ...... rom a Spanish TTD Group Study.
@en
P2093
P2860
P1433
P1476
First-line cetuximab plus cape ...... rom a Spanish TTD Group Study.
@en
P2093
Bartomeu Massuti
Cristina Grávalos
Eduardo Díaz-Rubio
Enrique Aranda
Eugenio Marcuello
Fernando Rivera
Javier Sastre
José L Manzano
Manuel Benavides
Manuel Hidalgo
P2860
P304
P356
10.1634/THEONCOLOGIST.2011-0406
P577
2012-02-23T00:00:00Z